Isis Advances Antisense Drug for Huntington’s Disease in Collaboration with Roche
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 17 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1925 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Isis Pharmaceuticals has partnered with Roche to advance the development of therapeutics for Huntington’s disease (HD) based on its antisense oligonucleotide (ASO) technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS